PAHC
NASDAQ · Pharmaceuticals
Phibro Animal Health Corp-A
$54.89
+1.71 (+3.22%)
Financial Highlights (FY 2026)
Revenue
969.21M
Net Income
36.09M
Gross Margin
31.6%
Profit Margin
3.7%
Rev Growth
+11.2%
D/E Ratio
2.52
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 31.6% | 31.6% | 36.7% | 36.7% |
| Operating Margin | 8.5% | 7.7% | 35.4% | 32.2% |
| Profit Margin | 3.7% | 3.5% | 25.7% | 26.0% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 969.21M | 871.51M | 1.31B | 972.76M |
| Gross Profit | 306.17M | 275.31M | 479.67M | 357.06M |
| Operating Income | 82.58M | 66.83M | 462.06M | 312.99M |
| Net Income | 36.09M | 29.21M | 335.32M | 253.19M |
| Gross Margin | 31.6% | 31.6% | 36.7% | 36.7% |
| Operating Margin | 8.5% | 7.7% | 35.4% | 32.2% |
| Profit Margin | 3.7% | 3.5% | 25.7% | 26.0% |
| Rev Growth | +11.2% | +11.2% | +2.9% | -6.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 597.32M | 597.32M | 399.08M | 413.63M |
| Total Equity | 237.44M | 237.44M | 1.04B | 1.11B |
| D/E Ratio | 2.52 | 2.52 | 0.38 | 0.37 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 116.70M | 99.69M | 482.41M | 394.81M |
| Free Cash Flow | — | — | 282.39M | 183.99M |